Results 81 to 90 of about 5,935 (185)

Intracoronary reopro during percutaneous coronary intervention in acute and stable patient can influence stent thrombosis formation (IRPASST) study

Heart Views, 2013
Background: In patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty, abciximab reduces major adverse cardiac events (MACE). Most clinical trials have studied mainly intravenous administration.
Mohammed Balghith, Ali Al-Ghamdi, El harif Zain, Ahmed Al-Saileek   +3 more
doaj  

Terapias emergentes: inhibidores de glicoproteína IIB/IIIA en ataque cerebrovascular agudo

Acta Neurológica Colombiana, 2010
El ataque cerebrovascular (ACV) es una causa común de morbilidad y mortalidad en el mundo. La terapia trom- bolítica con (r-TPA), es la única terapia aprobada para el tratamiento del ACV y esta terapia solo se logra aplicar en el 2 % de los pacientes ...
Juliana Coral Casas
doaj   +2 more sources

Clinical impact of abciximab on long-term outcome after complex coronary angioplasty

, 2003
Glycoprotein IIb/IIIa receptor antagonists, such as abciximab, are used to reduce major adverse cardiac events (MACES) in patients undergoing percutaneous transluminal coronary angioplasty.
Versteeg, DIK, Tio, RA, Wijpkema, JS, Van Boven, AJ, Jessurun, GAJ, Hautvast, RWM   +5 more
core   +1 more source

Abciximab readministration: A single-operator community-hospital experience.

, 1999
Abciximab, a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor, reduces ischemic complications of coronary interventions after first administration.
Chang, K S, Arjomand, H, Magsi, Z M, Mascarenhas, D A   +3 more
core   +1 more source

Vergleich der intrakoronaren zur intravenösen Abciximab-Bolusgabe bei Patienten mit einem akuten Koronarsyndrom

, 2007
In patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty, abciximab reduces major adverse cardiac events (MACE). Clinical trials have studied intravenous administration only.
Schaible, Stefan
core   +1 more source

Intracoronary versus intravenous abciximab administration in STEMI patients: overview of current status and open questions [PDF]

, 2012
Objectives: To perform a systematic review to provide rationale for intracoronary (IC) abciximab administration in patients with ST-segment elevation myocardial infarction (STEMI), to summarize recent studies comparing IC vs.
Goch, Aleksander, Grześk, Grzegorz, Navarese, Eliano Pio, Kubica, Aldona, Kubica, Jacek, Koziński, Marek   +5 more
core  

Paradoxical Platelet Activation Was not Observed on Dissociation of Abciximab from GPIIb-IIIa Complexes

, 2002
SummaryThe ability of abciximab to bind and dissociate from platelets raises the question of the conformational state of GPIIb-IIIa complexes losing abciximab and the risk of paradoxical drug-induced platelet activation.
Christel Poujol, Serge Ndoko, Alan Nurden, Paquita Nurden, Robert Combrié   +4 more
core   +1 more source

Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

, 2015
Background: Although intracoronary abciximab failed to improve prognosis compared with intravenous route in unselected ST-segment elevation myocardial infarction (STEMI) patients, little is known about the role of intracoronary abciximab in diabetic ...
Eitel, Ingo, GALASSO, Gennaro, Abreu Gonzalez, Pedro, de Smet, Bart J. G. L., Mahmoud, Karim D., Iversen, Allan Zeeberg, PICCOLO, RAFFAELE, Dominguez Rodriguez, Alberto, PISCIONE, Federico, Dominguez-Rodriguez, Alberto, Thiele, Holger, Abreu-Gonzalez, Pedro, Gu, Youlan L.   +12 more
core   +1 more source

Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel or both?

Vascular Health and Risk Management, 2006
Matthew A Silva1, Jennifer L Donovan1,3, Pritesh J Gandhi2, Gregory A Volturo31Massachusetts College of Pharmacy and Health Sciences, Department of Pharmacy Practice, Worcester, MA, USA; 2Alexion Pharmaceuticals, Inc., Cheshire, CT, USA; 3UMass Memorial ...
Matthew A Silva, Jennifer L Donovan, Pritesh J Gandhi, Gregory A Volturo   +3 more
doaj  

Time and Dose Dependent Augmentation of Inhibitory Effects of Abciximab by Aspirin

, 2001
SummaryAspirin and abciximab independently decrease the incidence of cardiac events. To identify potential interactions, antiplatelet effects of abciximab were characterized in blood from healthy subjects given aspirin. Platelet activation was determined
David Schneider, Douglas Taatjes, Burton Sobel, Michael Holmes, Patricia Baumann   +4 more
core   +1 more source